Literature DB >> 31309751

[Progress on medical treatment in the management of adenomyosis].

Kalianee Devi Baboo1, Zhengyun Chen1, Xinmei Zhang1.   

Abstract

Drug therapy plays an important role in alleviating the symptoms related to adenomyosis, improving the curative effect of surgery, delaying the progress of disease and promoting assisted reproduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice to control pain associated with adenomyosis, and are the only choice for patients with recent fertility requirements; steroid hormones, gonadotropin releasing hormone agonists and mifepristone can effectively relieve pain and control uterine bleeding, among which oral contraceptives, levonorgestrel-releasing intranterine system (Mirena) and dienogest are more effective and commonly used in clinic. Drug selection should be based on patient's age, symptoms, uterine size, fertility requirements and economical conditions. At present, there is no specific drug for adenomyosis, and symptoms are easy to recur after drug withdrawal, so the long-term drug use needs further study.

Entities:  

Mesh:

Year:  2019        PMID: 31309751      PMCID: PMC8800645          DOI: 10.3785/j.issn.1008-9292.2019.04.04

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  29 in total

1.  Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia.

Authors:  R S Newfield; I M Spitz; C Isacson; M I New
Journal:  Clin Endocrinol (Oxf)       Date:  2001-03       Impact factor: 3.478

2.  The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.

Authors:  Jie Sheng; Wei Yuan Zhang; Jian Ping Zhang; Dan Lu
Journal:  Contraception       Date:  2008-12-11       Impact factor: 3.375

3.  [A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia].

Authors:  L Li; J H Leng; J H Shi; J J Zhang; S Z Jia; X Y Li; Y Dai; J R Zhang; T Li; X X Xu; Z Z Liu; S S You; X Y Chang; J H Lang
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2016-06-25

Review 4.  Medical treatment for adenomyosis and/or adenomyoma.

Authors:  Kuan-Hao Tsui; Wen-Ling Lee; Chih-Yao Chen; Bor-Chin Sheu; Ming-Shyen Yen; Ting-Chang Chang; Peng-Hui Wang
Journal:  Taiwan J Obstet Gynecol       Date:  2014-12       Impact factor: 1.705

5.  Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.

Authors:  S J Pierce; M R Gazvani; R G Farquharson
Journal:  Fertil Steril       Date:  2000-11       Impact factor: 7.329

6.  Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis.

Authors:  Ki Hwan Lee; Jang Kew Kim; Min A Lee; Young Bok Ko; Jung Bo Yang; Byung Hun Kang; Heon Jong Yoo
Journal:  Arch Gynecol Obstet       Date:  2016-05-07       Impact factor: 2.344

7.  Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.

Authors:  Khaleque Newaz Khan; Michio Kitajima; Koichi Hiraki; Akira Fujishita; Ichiro Sekine; Tadayuki Ishimaru; Hideaki Masuzaki
Journal:  Hum Reprod       Date:  2009-12-15       Impact factor: 6.918

Review 8.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

9.  Adenomyosis in the adolescent population: a case report and review of the literature.

Authors:  S Paul Itam; Leslie Ayensu-Coker; Judith Sanchez; Robert K Zurawin; Jennifer E Dietrich
Journal:  J Pediatr Adolesc Gynecol       Date:  2009-07-08       Impact factor: 1.814

Review 10.  Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.

Authors:  Bernardine H Stegeman; Marcos de Bastos; Frits R Rosendaal; A van Hylckama Vlieg; Frans M Helmerhorst; Theo Stijnen; Olaf M Dekkers
Journal:  BMJ       Date:  2013-09-12
View more
  3 in total

1.  Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis.

Authors:  Haoxian Wang; Jihong Zhang; Qinqin Zhu; Xianyun Fu; Chenjie Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-26       Impact factor: 2.629

2.  Analysis of the Mechanism of GuizhiFuling Wan in Treating Adenomyosis Based on Network Pharmacology Combined with Molecular Docking and Experimental Verification.

Authors:  Yaxin Shi; Chengyuan Zhang; Xin Wang; Zilu Wang; Yiran Zhang; Zhiyong Liu; Xin Wang; Wei Shi
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-26       Impact factor: 2.650

3.  ITRAQ-based proteomics analysis of tanshinone IIA on human ectopic endometrial stromal cells of adenomyosis.

Authors:  Yong Luo; Zeng-Ming Li; Li-Ping Li; Yang Zou; Xiao-Yun Xu; Zi-Yu Zhang; Fa-Ying Liu; Yan Xiong; Lei Wan
Journal:  Arch Gynecol Obstet       Date:  2021-01-20       Impact factor: 2.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.